MRIdian integrates MRI technology, radiation delivery and proprietary software to locate, target and track the position and shape of tumors while radiation is delivered. MRIdian is the only clinically-available system in the world that can provide continuous soft-tissue imaging during radiation treatment. This means that, for the first time, doctors are able to see the tumor they are treating continuously, enabling personalized and adaptive radiation therapy.
VUmc intends to use the machine for patients with tumors in the abdomen and chest such as bladder cancer, prostate cancer, renal cancer, pancreatic cancer, rectal cancer, lung cancer and liver metastases. An area of particular interest to the VUmc team is MRI-guided stereotactic body radiotherapy (SBRT), which is the treatment of cancer using higher doses of radiation in a shorter course of therapy than traditional radiation therapy.
Earlier this year the radiotherapy department of the VUmc organized an international symposium on SBRT where more than 240 participants from 26 different countries gathered to listen to leading experts sharing their experience. A part of the day was dedicated to stereotactic radiotherapy using MRI-guidance, which the center has termed "SMART" for stereotactic MRI-guided and adaptive radiotherapy.
"Our team has now installed MRIdian systems in each of our major markets – North America, Asia-Pacific, and Europe – and we congratulate VUmc on their leadership in being the first in Europe," said Chris A. Raanes, president and CEO of ViewRay Incorporated. "The radiotherapy department of VUmc is known worldwide for its expertise in high-precision radiotherapy and for being at the forefront of new developments in cancer treatment."
ViewRay, Inc. of Cleveland, Ohio, is a medical device company that develops advanced radiation therapy technology for the treatment of cancer. The MRIdian® system provides continuous soft-tissue imaging during treatment, using MRI-guided radiation therapy, so that clinicians are able to see where the actual radiation dose is being delivered and adapt to changes in the patient's anatomy.
ViewRay and MRIdian are registered trademarks of ViewRay, Inc.
Forward Looking Statements:
This press release contains forward-looking statements. Statements in this press release that are not purely historical are forward-looking statements. Such forward-looking statements include, among other things, references to the benefits of MRI guidance and the types of cancers to be treated on the MRIdian at VUmc. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, the ability to raise the additional funding needed to continue to pursue ViewRay's business and product development plans, the inherent uncertainties associated with developing new products or technologies, the ability to commercialize the MRIdian linac technology, competition in the industry in which ViewRay operates and overall market conditions. These forward-looking statements are made as of the date of this press release, and ViewRay assumes no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements, except as required by law. Investors should consult all of the information set forth herein and should also refer to the risk factor disclosure set forth in the reports and other documents ViewRay files with the SEC available at www.sec.gov.
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/first-mridian-system-installed-in-europe-at-vu-university-medical-center-of-amsterdam-300240952.html
SOURCE ViewRay, Inc.